Plain English Summary
Background and study aims
Venous leg ulcers (VLUs) affect almost 400,000 people over the age of 65 in the UK. These are triggered by inadequate blood flow through the veins, causing pain, mobility restrictions, devastation and social isolation. Each VLU costs about £2k/year to the NHS, while annual healthcare costs are about £400 million. Compression therapy (most commonly stockings or bandages) are used to treat VLUs: although healing rates are good, ulcers often return. Moreover, many remain open for up to 1 year, needing about 50 visits to heal. Consequently, supportive therapies to compression are needed to reduce healing times. Exercise may provide an answer. The researchers recently examined if it was possible to use a 12-week, community-based exercise programme, along with compression therapy, to treat VLUs. The programme was safe, participants enjoyed it and were attending their sessions. The programme also offered reduced healing times and savings to the NHS of up £875/ulcer. Nevertheless, the programme wasn’t accessible by people who are house-bound and could otherwise do the programme exercises. Therefore, the researchers need to design and explore the practicality of a home-based exercise programme, which would be offered to patients who cannot travel. This is worth trying, as findings indicate that 74% of house-bound people with VLUs would willingly try such a programme.
Who can participate?
Patients aged 18 and over with at least one VLU
What does the study involve?
In Phase 1, patients help design the home-based exercise programme. In Phase 2, patients are randomly allocated to one of the two study groups to receive home-based exercise and standard care, or standard care only, for 12 weeks with an extra 3 weeks to allow for missed sessions. Patients are assessed at 3 and 6 months to explore any changes that might take place in the lower leg physiology and quality of life. Finally, in Phase 3 the researchers talk to Phase 2 participants to hear about their study experience and refine the programme further.
What are the possible benefits and risks of participating?
Not provided at time of registration
Where is the study run from?
Sheffield Hallam University (UK)
When is the study starting and how long is it expected to run for?
December 2018 to September 2022
Who is funding the study?
National Institute for Health Research (NIHR) (UK)
Who is the main contact?
1. Dr Markos Klonizakis
m.klonizakis@shu.ac.uk
2. Emma McIntosh
E.mcintosh@shu.ac.uk
Trial website
Contact information
Type
Scientific
Primary contact
Dr Markos Klonizakis
ORCID ID
http://orcid.org/0000-0002-8864-4403
Contact details
Department of Nursing and Midwifery
Faculty of Health and Wellbeing
Sheffield Hallam University
Sheffield
S10 2NA
United Kingdom
+44 (0)114 225 5697
m.klonizakis@shu.ac.uk
Type
Scientific
Additional contact
Ms Emma McIntosh
ORCID ID
Contact details
Sheffield Hallam University
A203
Collegiate Hall
Collegiate Crescent
Sheffield
S10 2BP
United Kingdom
-
E.mcintosh@shu.ac.uk
Additional identifiers
EudraCT number
Nil known
ClinicalTrials.gov number
Nil known
Protocol/serial number
CPMS: 42699
Study information
Scientific title
Development and feasibility-testing of a home-based exercise training and compression hosiery intervention for people with venous ulceration
Acronym
FISCU II
Study hypothesis
Venous leg ulcers (VLUs) affect almost 400,000 people over the age of 65 in the U.K. These are triggered by inadequate blood flow through the veins, causing pain, mobility restrictions, devastation and social isolation. Each VLU costs about £2k/year to the NHS, while annual healthcare costs are about £400 million. Compression therapy (most commonly stockings or bandages) are used to treat VLUs: although healing rates are good, ulcers often return. Moreover, many remain open for up to 1 year, needing about 50 visits to heal. Consequently, supportive therapies to compression are needed to reduce healing times. Exercise may provide an answer. The researchers recently examined if it was possible to use a 12-week, community-based exercise programme, along with compression therapy, to treat VLUs. The programme was safe, participants enjoyed it and were attending their sessions. The programme also offered reduced healing times and savings to the NHS of up £875/ulcer. Nevertheless, the programme wasn’t accessible by people who are house-bound and could otherwise do the programme exercises. Therefore, the researchers need to design and explore the practicality of a home-based exercise programme, which would be offered to patients who cannot travel. This is worth trying, as findings indicate that 74% of house-bound people with VLUs would willingly try such a programme. In Phase 1, people with VLUs will help to design the home-based exercise programme. In Phase 2, the researchers will recruit people with VLUs in Sheffield, who although house-bound, can do some exercises (flexibility, stretching and chair-aerobics) and are mentally healthy. The researchers will have the intervention tested and explore any changes that might take place in the lower leg physiology and quality of life. Finally, in Phase 3 the researchers will talk to Phase 2 participants to hear about their study experience and refine the programme further.
The main research question for this study is: Can we develop and pilot test a home-based, exercise intervention for home-bound people with VLUs?
Phase 1: The primary aim of Phase 1 will be to develop, with the support of people with VLUs in specially-arranged focus groups and interviews, a home-based, exercise intervention, modelled on the exercises delivered on the successful FISCU community-based exercise programme. Specific objectives will include: a) the definition of the regularity/mode/type of support offered by the intervention facilitators to participants, b) the choice of exercises implemented in the home-based programme (based on exercises that are appropriate to meet the programme's targets), c) the adaptation of materials and resources provided to participants and d) the retention/adherence promotion strategy/monitoring followed during home-based delivery
Phase 2: The primary aims for Phase 2 are to estimate the rates of compliance and retention for a definitive trial. Specific objectives include: i) to assess the ease of data collection required for each potential primary outcome (including participant burden and impact of participant’s cognition, assessed via qualitative data). ii) to evaluate quantitatively (i.e. compliance) the proposed exercise intervention
Phase 3: The primary aims for Phase 3 will be to conduct post-intervention interviews with participants and using the obtained information to refine the design and delivery of the home-based programme. The specific objective for Phase 3 will be to evaluate qualitatively (i.e. direct patient experience of the interventions) and then carry out the intervention refinement task
Ethics approval
Approved 24/04/2019, London Surrey Research Ethics Committee (Tel: +44 (0)20 7104 8222; Email:
NRESCommittee.SECoast-Surrey@nhs.net), ref: 18/LO/1983
Study design
Randomised; Both; Design type: Treatment, Process of Care, Complex Intervention, Physical, Rehabilitation, Qualitative
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Not available in web format, please use the contact details to request a patient information sheet
Condition
Venous leg ulcers
Intervention
Following baseline measurements, participants (n=40) will be randomised remotely to one of the two study groups (Group A: home-based exercise and standard care, n=20; Group B: standard care only, n=20) by the study statistician (to ensure allocation concealment), using a computer programme (nQuery Advisor 6.0, Statistical Solutions, Ireland) to generate stratified block randomisation with variable block-size. Stratification will be on the basis of ulcer size (e.g., ulcer size greater than 3 cm or between 1 and 3 cm in any direction).
Total duration of treatment: 12 weeks with an extra 3 weeks to allow for missed sessions
Follow-up for both groups: assessment at 3 months and 6 months after baseline
Intervention type
Other
Phase
Drug names
Primary outcome measure
1. Recruitment rates measured as rate of invited participants who are eligible and consenting and reported in Consolidated Standards of Reporting Trials (CONSORT) flowchart
2. Acceptability of procedures assessed by examining reasons for drop-out in discontinuing participants and comparing attrition between groups
3. Suitability of measurement procedures evaluated by completion rates and reasons for missing data
4. Attrition rates established as discontinuation of intervention and loss to follow-up measurement
5. The acceptability of the exercise programme assessed by using session compliance data and participant feedback via one-to-one, semi-structured interviews conducted after the 3-month follow-up visit
6. Exercise safety assessed by exploring reasons for drop-out from the intervention and the number and type of adverse events that occur in each group
7. Group contamination assessed by the number of people in the control group who take up exercise as a result of their study participation
Secondary outcome measures
1. Health-related quality of life assessed using EQ-5D-5L and VEINES-QOL at baseline and at 3 and 6 months
2. Physical fitness assessed using Senior Fitness Test at baseline and at 3 and 6 months
Overall trial start date
03/12/2018
Overall trial end date
01/09/2022
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
1. Are at least 18 years of age
2. Have at least one venous leg ulcer of primarily venous aetiology (determined by a clinician) with a maximum diameter ≥ 1 cm
3. Have an ankle brachial pressure index (ABPI) ≥ 0.8 (recorded within the previous 3 months)
4. Are able/willing to tolerate lower-limb compression
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
Planned Sample Size: 58; UK Sample Size: 58
Participant exclusion criteria
1. Are unsuitable/unable to exercise (determined by a clinician at screening or baseline)
2. Are unable/unwilling to tolerate lower-limb compression
3. Have insulin-controlled diabetes mellitus
4. Are pregnant
5. Have coexisting skin conditions, vasculitis, deep venous occlusion or malignant/atypical ulceration (if suitable otherwise, participants may be re-considered at a later stage)
6. Require major surgery within 3 months from eligibility assessment
7. Have a leg ulcer with a maximum diameter ≤1 cm
8. Have had an ulcer at the same site within the previous 3 months
9. Are unable or do not wish to consent to participation in the trial
Recruitment start date
01/09/2019
Recruitment end date
01/02/2022
Locations
Countries of recruitment
United Kingdom
Trial participating centre
Centre for Sports and Exercise Science (CSES)
Sheffield Hallam University
Collegiate Campus
Collegiate Crescent
Sheffield
S10 2BP
United Kingdom
Sponsor information
Organisation
Sheffield Health & Social Care NHS Foundation Trust
Sponsor details
c/o Dr Michelle Horspool
Fulwood House
Old Fulwood Road
Sheffield
S10 3TH
United Kingdom
+44 (0)114 226 3338
Michelle.Horspool@shsc.nhs.uk
Sponsor type
Hospital/treatment centre
Website
Funders
Funder type
Government
Funder name
NIHR Central Commissioning Facility (CCF); Grant Codes: PB-PG-0418-20021
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
The researchers aim to publish their research in a high impact peer-reviewed journal. No addition files will be available for upload.
IPD sharing statement
The datasets generated during and/or analysed during the current study are not expected to be made available due to these being used for consecutive grant applications following the end of the current one and lack of relevant ethical approval.
Intention to publish date
01/02/2024
Participant level data
Not expected to be available
Basic results (scientific)
Publication list